You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Details for Patent: RE43711

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent RE43711 protect, and when does it expire?

Patent RE43711 protects INBRIJA and is included in one NDA.

This patent has twenty patent family members in twelve countries.

Summary for Patent: RE43711

Title:	Pulmonary delivery for levodopa
Abstract:	In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
Inventor(s):	Jackson; Blair (Sudbury, MA), Bennett; David J. (Brighton, MA), Bartus; Raymond T. (San Diego, CA), Emerich; Dwaine F. (Cranston, RI)
Assignee:	Civitas Therapeutics, Inc. (Chelsea, MA)
Application Number:	13/274,787
Patent Claim Types: see list of patent claims	Use; Formulation; Delivery; Dosage form;

Drugs Protected by US Patent RE43711

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Merz Pharms	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent RE43711

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003218307	⤷ Sign Up
Canada	2478980	⤷ Sign Up
Cyprus	1118517	⤷ Sign Up
Denmark	1531798	⤷ Sign Up
Denmark	2630954	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.